A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany

NCT05305664 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperlipoproteinemia(a)

Interventions

DRUG: Pelacarsen (TQJ230) 80 mg s.c.
DRUG: Corresponding Placebo

Sponsor

Novartis Pharmaceuticals